Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge
Authors:
- A. Barry KayAKA. Barry Kay
- 1 September 2005
- journal article
- clinical trial
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 116 (3) , 558-564
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Omalizumab-induced reductions in mast cell FcεRI expression and functionJournal of Allergy and Clinical Immunology, 2004
- Omalizumab treatment downregulates dendritic cell FcεRI expressionJournal of Allergy and Clinical Immunology, 2003
- Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trialThe Lancet, 2002
- Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthmaJournal of Allergy and Clinical Immunology, 2001
- Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic responseThe Lancet, 2000
- Repeated allergen challenge as a new research model for studying allergic reactionsClinical & Experimental Allergy, 1999
- Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis☆☆☆★★★Journal of Allergy and Clinical Immunology, 1997
- High affinity human IgE receptor (Fc epsilon RI). Analysis of functional domains of the alpha-subunit with monoclonal antibodiesJournal of Biological Chemistry, 1991
- Eosinophils and T-lymphocytes in late-phase allergic reactionsJournal of Allergy and Clinical Immunology, 1990
- Late cutaneous allergic responses in isolated IgE-dependent reactionsJournal of Allergy and Clinical Immunology, 1973